10-K/A: Intelligent Bio Solutions Files 10-K/A Amendment

Intelligent Bio Solutions Inc. files Amendment No. 1 to its Form 10-K for the fiscal year ended June 30, 2026, primarily to revise executive compensation disclosures, related party transaction policies, and exhibit index.

Summary

• This filing is an amendment (Amendment No. 1) to the Annual Report on Form 10-K for the fiscal year ended June 30, 2026, for Intelligent Bio Solutions Inc.
• The amendment specifically revises Item 11 (Executive Compensation) to remove duplicate disclosure regarding outstanding equity awards.
• It also revises Item 13 to add disclosure on capital raising transactions involving significant shareholders, clarify related party transaction approval processes, and make other clarifying revisions.
• The Exhibit Index in Item 15 is updated to correct duplicate entries and replace a certificate with the Amended and Restated Certificate of Incorporation.
• New certifications from the principal executive officer and principal financial officer, pursuant to Section 302 of the Sarbanes-Oxley Act, are included.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to its nature as an amendment and the focus on executive compensation and related party transactions rather than core operational or financial performance updates.

Positives

• The company is providing updated disclosures regarding its executive compensation and related party transaction policies.
• The amendment clarifies the process for approving related party transactions, aiming for greater transparency.
• New certifications from key officers under Sarbanes-Oxley Act Section 302 are provided, affirming the accuracy of the report.
• The 2019 Long Term Incentive Plan has seen several amendments to increase the aggregate number of shares available for issuance, supporting future equity compensation.

Negatives

• The filing is an amendment, indicating potential initial omissions or errors in the original 10-K filing.
• The focus on executive compensation and related party transactions, rather than core business performance, may suggest a lack of significant operational updates.
• The aggregate market value of common stock held by non-affiliates was $11,712,017 as of December 31, 2025, indicating a relatively small market capitalization.

Risks

• The company's reliance on stock-based compensation, as detailed in the 2019 Long Term Incentive Plan, could lead to dilution for existing shareholders.
• The definition of 'Change in Control' in executive employment agreements could trigger significant severance payments if certain acquisition thresholds are met.
• The company has engaged in multiple capital raising transactions, including warrant exercises and private placements, which can be indicative of ongoing funding needs.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. It primarily focuses on amendments to previous disclosures and corporate governance matters.

Management Comments

• Spiro Sakiris certifies that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading.
• Harry Simeonidis certifies that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading.

Industry Context

StockSavvy.ai notes that amendments to 10-K filings, especially those focusing on executive compensation and related party transactions, are common for smaller reporting companies as they refine disclosures and corporate governance practices. The inclusion of detailed stock award information aligns with industry trends in using equity as a key component of executive compensation.

Corporate Governance

Related Party Transactions

• Alyeska Master Fund, L.P., a greater than 5% beneficial owner, participated in the 2025 Warrant Inducement Transaction, exercising warrants and prepaying for others, generating approximately $831,368 in gross proceeds.
• Alyeska Master Fund, L.P. participated in the December Private Placement by purchasing shares and warrants for approximately $5.0 million.
• During fiscal year ended June 30, 2026, Alyeska exercised warrants to purchase 216,247 shares for an aggregate exercise price of $118,109.

Stakeholder Impact

• Shareholders may see potential dilution from the ongoing issuance of equity awards under the 2019 Long Term Incentive Plan.
• The clarification of related party transaction approval processes could increase investor confidence in corporate governance.
• Executive officers and directors will be subject to the company's recoupment policy for incentive-based compensation.
• The capital raises detailed may impact the ownership structure and potentially the share price.

Next Steps

• The company has amended its Form 10-K to include revised disclosures on executive compensation, related party transactions, and exhibits.
• New Sarbanes-Oxley certifications have been filed by the CEO and CFO.
• The company will continue to operate under its existing 2019 Long Term Incentive Plan, with ongoing amendments to the plan's share availability.

Key Dates

Keywords

Executive Compensation, Related Party Transactions, Sarbanes-Oxley Act, Form 10-K Amendment, Equity Awards, Capital Raise, Corporate Governance, Stock Incentive Plan